Tuesday, July 16, 2024

Health Insurance Covers Over 90% of Medication Costs for Special Patients in Iran

Similar articles

The head of the Food and Drug Administration (FDA) in Iran announced that over 90% of the medication costs for special patients are covered by health insurance. This means that patients are responsible for paying less than 10% of their medication costs. This substantial level of support is designed to ensure that individuals with chronic and critical conditions receive the necessary treatments without experiencing a significant financial burden. By reducing out-of-pocket expenses, the policy aims to improve access to essential medications for those in need.

Seyed Heidar Mohammadi, the head of the FDA, elaborated on this initiative by highlighting that some imported medications, primarily intended for special patients, are funded with government currency. This strategic approach ensures that 90% of the final cost of these medications is covered by health insurance organizations. As a result, the patient’s contribution is minimized, often being either zero or at most 10% of the medication price. This policy is specifically designed to alleviate the financial burden on patients with serious health conditions, ensuring they can access vital treatments without financial stress.

Mohammadi emphasized that this policy is part of a broader effort to enhance the healthcare system in Iran, particularly for those facing severe health challenges. By subsidizing a significant portion of medication costs, the government aims to provide equitable healthcare access and improve overall public health outcomes. The initiative reflects a commitment to supporting vulnerable populations and reducing the economic strain on families dealing with chronic illnesses.

Health Insurance in Iran Ensures Access to High-Cost Medications with Over 90% Coverage

The policy also addresses the availability of high-cost medications that are often necessary for treating complex conditions. By funding these medications with government resources and ensuring substantial health insurance coverage, the program aims to remove barriers to access and ensure that all patients receive the treatments they need. This approach not only improves the quality of care but also supports the financial well-being of patients and their families.

The implementation of this policy represents a significant step forward in Iran’s healthcare system, demonstrating a commitment to patient-centered care and financial protection. By covering the majority of medication costs, the government is taking proactive measures to support those with serious health conditions, ensuring they can manage their health without facing prohibitive costs. This initiative is a critical component of Iran’s broader healthcare strategy, aiming to create a more inclusive and supportive system for all citizens.

Seyed Heidar Mohammadi’s announcement highlights a crucial development in Iran’s healthcare policy, with over 90% of medication costs for special patients being covered by health insurance. This policy, funded by government resources, ensures that patients pay minimal out-of-pocket expenses, thus alleviating financial burdens and improving access to essential treatments. The initiative underscores the government’s commitment to providing comprehensive healthcare support, particularly for those with chronic and critical conditions.

Health Insurance

Stringent Evaluation Ensures Cost-Effective Medications Covered by Health Insurance in Iran

Before medications are included in the national drug list and consequently covered by health insurance, their cost-effectiveness and impact on the disease must be established and proven. Therefore, a drug is only introduced to the market with health insurance support if there is scientific and economic justification for its use in treating the condition. This process ensures that only effective and economically viable treatments are made available to patients.

In some rare cases where the cost-effectiveness of a medication has not been proven to insurance organizations, and the medication is prescribed by doctors, the FDA imports the drug on a single-prescription basis. This provision allows for flexibility in providing necessary treatments that may not yet be broadly accepted by health insurance entities but are deemed essential by healthcare providers.

You can follow our news on our Telegram and LinkedIn accounts.

If a medication’s effectiveness is proven by doctors, it undergoes evaluations by economic and medical committees. These committees assess the drug’s cost-effectiveness and therapeutic efficacy. If approved by both commissions, insurance organizations accept the medication, and it is covered by health insurance. However, as mentioned, such cases are very rare, indicating the stringent assessment process in place to ensure only the most effective and economical treatments are insured.

Comprehensive health insurance coverage for medication costs plays a crucial role in ensuring that patients with special needs receive timely and appropriate treatments without facing financial hardship. This policy reflects a commitment to improving health outcomes and the quality of life for individuals with chronic and serious health conditions.

 

Resource: Mehr News Agency, June 26, 2024

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article